Paolo Antonio A.
- Country
- Italy
- Department
- s.c. melanoma, immunoterapia oncologica e terapie innovative
Research Overview
- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
- Neoadjuvant Immunotherapy with Nivolumab, Ipilimumab, MDNA11, and Tocilizumab in High-Risk Resectable Melanoma: A Phase Ib Multicentre Randomised Trial
- Phase 2 Open‑Label Study of BMS‑986504 Monotherapy and Combination Therapy in Advanced/Metastatic Solid Tumors with Homozygous MTAP Deletion
Data & Insights
Has run more than one trial at 149 of 293 partner sites.
Specializations
Melanoma Research
This investigator specializes in the treatment of advanced melanoma, with particular emphasis on both cutaneous melanoma and uveal melanoma. Their research encompasses various stages of disease, from early-stage resectable cases to metastatic presentations.
- BRAF-mutated melanoma interventions
- Immunotherapy combinations
- Brain metastases management
Skin Cancer Expertise
The investigator conducts research in various types of skin malignancies, including squamous cell carcinoma and Merkel cell carcinoma. Their work focuses on both localized and advanced disease states.
- Neoadjuvant therapy approaches
- Novel therapeutic combinations
- High-risk disease management
Advanced Solid Tumors
The investigator works extensively with KRAS-mutated tumors and various forms of advanced solid malignancies. Their research includes evaluation of novel therapeutic approaches and targeted treatments.
- Molecular targeted therapies
- Immunotherapy combinations
- Biomarker-driven treatments
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.